Equities research analysts expect that Bristol-Myers Squibb (NYSE:BMY) will post sales of $5.10 billion for the current quarter, Zacks reports. Three analysts have issued estimates for Bristol-Myers Squibb’s earnings. The lowest sales estimate is $4.93 billion and the highest is $5.24 billion. Bristol-Myers Squibb posted sales of $4.93 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.4%. The business is expected to announce its next earnings report before the market opens on Thursday, April 26th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full year sales of $21.48 billion for the current financial year, with estimates ranging from $20.86 billion to $21.86 billion. For the next financial year, analysts forecast that the company will post sales of $23.48 billion per share, with estimates ranging from $21.97 billion to $24.58 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Bristol-Myers Squibb.

How to Become a New Pot Stock Millionaire

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. Bristol-Myers Squibb’s revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 EPS.

BMY has been the topic of several research analyst reports. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective on the stock. in a report on Friday, December 22nd. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. BMO Capital Markets restated a “sell” rating and issued a $52.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, January 22nd. Credit Suisse Group set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Finally, Leerink Swann boosted their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $66.45.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in shares of Bristol-Myers Squibb by 108.5% during the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares in the last quarter. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 5.0% during the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after buying an additional 4,945,515 shares in the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 2,990.5% during the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Bristol-Myers Squibb by 42,071.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares in the last quarter. 71.51% of the stock is owned by institutional investors.

Shares of BMY opened at $54.08 on Tuesday. The stock has a market capitalization of $95,750.99, a P/E ratio of 17.97, a P/E/G ratio of 1.52 and a beta of 0.96. Bristol-Myers Squibb has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.96%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

TRADEMARK VIOLATION NOTICE: “Analysts Expect Bristol-Myers Squibb (BMY) Will Announce Quarterly Sales of $5.10 Billion” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2018/04/17/analysts-expect-bristol-myers-squibb-bmy-will-announce-quarterly-sales-of-5-10-billion.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.